{
    "id": 30577,
    "fullName": "FAT1 mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "FAT1 mutant indicates an unspecified mutation in the FAT1 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 2195,
        "geneSymbol": "FAT1",
        "terms": [
            "FAT1",
            "CDHF7",
            "CDHR8",
            "FAT",
            "hFat1",
            "ME5"
        ]
    },
    "variant": "mutant",
    "createDate": "07/23/2019",
    "updateDate": "07/23/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 17848,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, FAT1 mutations were associated with improved durable clinical benefit (71.4% vs 22.7%, p=0.01) and objective response rate (57.1% vs 15.2%, p=0.02) compared to wild-type in non-small cell lung cancer patients treated with immunotherapies, including Tecentriq (atezolizumab) (n=5), Opdivo (nivolumab) (n=17), Keytruda (pembrolizumab) (n=36), and Camrelizumab (SHR-1210) (n=20) (PMID: 31085721).",
            "molecularProfile": {
                "id": 32798,
                "profileName": "FAT1 mutant"
            },
            "therapy": {
                "id": 1201,
                "therapyName": "Atezolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15767,
                    "pubMedId": 31085721,
                    "title": "Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31085721"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17850,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, FAT1 mutations were associated with improved durable clinical benefit (71.4% vs 22.7%, p=0.01) and objective response rate (57.1% vs 15.2%, p=0.02) compared to wild-type in non-small cell lung cancer patients treated with immunotherapies, including Tecentriq (atezolizumab) (n=5), Opdivo (nivolumab) (n=17), Keytruda (pembrolizumab) (n=36), and Camrelizumab (SHR-1210) (n=20) (PMID: 31085721).",
            "molecularProfile": {
                "id": 32798,
                "profileName": "FAT1 mutant"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15767,
                    "pubMedId": 31085721,
                    "title": "Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31085721"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17849,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, FAT1 mutations were associated with improved durable clinical benefit (71.4% vs 22.7%, p=0.01) and objective response rate (57.1% vs 15.2%, p=0.02) compared to wild-type in non-small cell lung cancer patients treated with immunotherapies, including Tecentriq (atezolizumab) (n=5), Opdivo (nivolumab) (n=17), Keytruda (pembrolizumab) (n=36), and Camrelizumab (SHR-1210) (n=20) (PMID: 31085721).",
            "molecularProfile": {
                "id": 32798,
                "profileName": "FAT1 mutant"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15767,
                    "pubMedId": 31085721,
                    "title": "Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31085721"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17851,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, FAT1 mutations were associated with improved durable clinical benefit (71.4% vs 22.7%, p=0.01) and objective response rate (57.1% vs 15.2%, p=0.02) compared to wild-type in non-small cell lung cancer patients treated with immunotherapies, including Tecentriq (atezolizumab) (n=5), Opdivo (nivolumab) (n=17), Keytruda (pembrolizumab) (n=36), and Camrelizumab (SHR-1210) (n=20) (PMID: 31085721).",
            "molecularProfile": {
                "id": 32798,
                "profileName": "FAT1 mutant"
            },
            "therapy": {
                "id": 6137,
                "therapyName": "Camrelizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15767,
                    "pubMedId": 31085721,
                    "title": "Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31085721"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 32798,
            "profileName": "FAT1 mutant",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}